troglitazone has been researched along with Liver Dysfunction in 15 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Troglitazone does not cause hepatotoxicity in normal healthy rodents, but it produces mitochondrial injury in vitro at high concentrations." | 5.34 | Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. ( Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007) |
| "Troglitazone is a thiazolidinedione antidiabetic agent with insulin-sensitizing activities that was withdrawn from the market in 2000 due to its association with idiosyncratic hepatotoxicity." | 5.33 | Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. ( Kaneko, S; Katoh, K; Maniratanachote, R; Nakajima, M; Sawazaki, T; Shibata, A; Tokudome, S; Wakasugi, T; Yamamori, I; Yokoi, T, 2005) |
| "Troglitazone is an agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), which has been shown to improve the metabolic control of type 2 diabetes." | 2.69 | Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. ( Ott, P; Ranek, L; Young, MA, 1998) |
| "Troglitazone does not cause hepatotoxicity in normal healthy rodents, but it produces mitochondrial injury in vitro at high concentrations." | 1.34 | Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. ( Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007) |
| "Troglitazone is a thiazolidinedione antidiabetic agent with insulin-sensitizing activities that was withdrawn from the market in 2000 due to its association with idiosyncratic hepatotoxicity." | 1.33 | Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. ( Kaneko, S; Katoh, K; Maniratanachote, R; Nakajima, M; Sawazaki, T; Shibata, A; Tokudome, S; Wakasugi, T; Yamamori, I; Yokoi, T, 2005) |
| "Troglitazone (TRG) is an antidiabetic agent that increases the insulin sensitivity of target tissues in non-insulin-dependent diabetes mellitus." | 1.32 | Troglitazone reduces heat shock protein 70 content in primary rat hepatocytes by a ubiquitin proteasome independent mechanism. ( Bharadwaj, LA; Davies, GF; Ovsenek, N; Roesler, WJ, 2003) |
| " In addition, we found that rosiglitazone, although less toxic in the study population, was cytotoxic to hepatocytes in some donors (EC(50)<100 microM)." | 1.31 | Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. ( Fackett, A; Hayden, MJ; Hewitt, NJ; Li, AP; Lloyd, S; Sakai, Y; Silber, PM, 2002) |
| "Troglitazone was effective in 394 (75%) of the 529 patients for whom an opinion was given." | 1.31 | Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting. ( Biswas, P; Shakir, SA; Wilton, LV, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 12 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lloyd, S | 1 |
| Hayden, MJ | 1 |
| Sakai, Y | 1 |
| Fackett, A | 1 |
| Silber, PM | 1 |
| Hewitt, NJ | 1 |
| Li, AP | 1 |
| Davies, GF | 1 |
| Roesler, WJ | 1 |
| Ovsenek, N | 1 |
| Bharadwaj, LA | 1 |
| Lee, WM | 1 |
| Watkins, PB | 1 |
| Maniratanachote, R | 1 |
| Shibata, A | 1 |
| Kaneko, S | 1 |
| Yamamori, I | 1 |
| Wakasugi, T | 1 |
| Sawazaki, T | 1 |
| Katoh, K | 1 |
| Tokudome, S | 1 |
| Nakajima, M | 1 |
| Yokoi, T | 1 |
| Johnson, DE | 1 |
| Rodgers, AD | 1 |
| Ong, MM | 1 |
| Latchoumycandane, C | 1 |
| Boelsterli, UA | 1 |
| Ikeda, T | 1 |
| Jaeschke, H | 1 |
| Murata, Y | 1 |
| Onji, M | 1 |
| Ott, P | 1 |
| Ranek, L | 1 |
| Young, MA | 1 |
| Kaplowitz, N | 1 |
| Everett, L | 1 |
| Galli, A | 1 |
| Crabb, D | 1 |
| Donnelly, R | 1 |
| Biswas, P | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity[NCT02353455] | 300 participants (Anticipated) | Observational | 2013-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for troglitazone and Liver Dysfunction
| Article | Year |
|---|---|
Drug-induced hepatotoxicity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Chemical and Drug Induced Liv | 2003 |
Computational toxicology: heading toward more relevance in drug discovery and development.
Topics: Animals; Chromans; Computational Biology; Drug Design; Drug-Related Side Effects and Adverse Reactio | 2006 |
[Abnormality of liver functional test in patients with drug-induced liver injury].
Topics: Acetaminophen; Analgesics; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cardiovas | 2007 |
The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Fatty Liver, Alcoholic; Kupffer Cells; Li | 2000 |
1 trial available for troglitazone and Liver Dysfunction
| Article | Year |
|---|---|
Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.
Topics: Adult; Aged; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Disease | 1998 |
10 other studies available for troglitazone and Liver Dysfunction
| Article | Year |
|---|---|
Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors.
Topics: Adenosine Triphosphate; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; C | 2002 |
Troglitazone reduces heat shock protein 70 content in primary rat hepatocytes by a ubiquitin proteasome independent mechanism.
Topics: Acetylcysteine; Animals; Blotting, Northern; Blotting, Western; Cells, Cultured; Chemical and Drug I | 2003 |
Idiosyncratic liver injury: challenges and approaches.
Topics: Adaptation, Physiological; Chemical and Drug Induced Liver Injury, Chronic; Chromans; Humans; Hypogl | 2005 |
Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Topics: Aged; Alanine Transaminase; Autoantibodies; Chemical and Drug Induced Liver Injury; Chromans; Diabet | 2005 |
Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.
Topics: Aconitate Hydratase; Animals; Chemical and Drug Induced Liver Injury; Chromans; Disease Models, Anim | 2007 |
SNP communications: coalition of toxicology and drug metabolism and pharmacokinetics.
Topics: Animals; Biotransformation; Chemical and Drug Induced Liver Injury; Chromans; Drug-Related Side Effe | 2007 |
Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Disease Models, Animal; Humans; Hypoglyce | 2007 |
Avoiding hepatic injury from drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Chemical and Drug Induced Liv | 1999 |
FDA reviews troglitazone.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Ag | 1999 |
Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Chromans; England; Fatigue; Female; Humans; Hyp | 2001 |